All In Biotech

Drug Trial Radar · NCT05007106

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 611 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

611

Actual

Start

Sep 16, 2021

Primary completion

Aug 5, 2025

Study completion Aug 5, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

Conditions

  • Uterine Cervical Neoplasms
  • Endometrial Neoplasms
  • Squamous Cell Carcinoma of Head and Neck
  • Gallbladder Neoplasms
  • Cholangiocarcinoma
  • Esophageal Neoplasms
  • Triple Negative Breast Neoplasms
  • Hepatocellular Carcinoma
  • Urinary Bladder Neoplasms
  • Ovarian Neoplasms
  • Stomach Neoplasms

Interventions

  • Pembrolizumab/Vibostolimab Co-FormulationBiological

    Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

  • PembrolizumabBiological

    Pembrolizumab 200 mg administered via IV infusion Q3W.

  • LenvatinibDrug

    Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

  • 5-FluorouracilDrug

    5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

  • CisplatinDrug

    Cisplatin administered via IV infusion

  • PaclitaxelDrug

    Paclitaxel administered via IV infusion at investigator's choice of dose

  • GemcitabineDrug

    Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

  • CarboplatinDrug

    Carboplatin administered via IV infusion at investigator's choice of dose and frequency

  • DocetaxelDrug

    For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

  • BevacizumabDrug

    Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

  • CapecitabineDrug

    Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

  • OxaliplatinDrug

    Oxaliplatin administered via IV infusion Q3W up to 35 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1Time frame: Up to approximately 24 months
  2. Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1Time frame: Up to approximately 24 months
  3. ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid TumorsTime frame: Up to approximately 24 months
  4. Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 MonthsTime frame: 9 months
  5. PFS Per RECIST 1.1 as Assessed by Investigator at 12 MonthsTime frame: 12 months

Locations

73 sites in 15 countries. Site status is shown where the registry gives one.

  • Alaska Womens Cancer Care ( Site 1016)

    Anchorage, Alaska

  • City of Hope Comprehensive Cancer Center ( Site 1001)

    Duarte, California

  • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente

    Orange, California

  • Karmanos Cancer Institute ( Site 1007)

    Detroit, Michigan

  • Memorial Sloan Kettering - Basking Ridge ( Site 1023)

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering - Monmouth ( Site 1022)

    Middletown, New Jersey

  • Memorial Sloan Kettering - Bergen ( Site 1025)

    Montvale, New Jersey

  • Memorial Sloan Kettering- Commack ( Site 1021)

    Commack, New York

  • Memorial Sloan Kettering - Westchester ( Site 1020)

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center ( Site 1002)

    New York, New York

  • Memorial Sloan Kettering - Nassau ( Site 1026)

    Uniondale, New York

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)

    Tulsa, Oklahoma

  • Sanford Cancer Center-Gynecologic Oncology ( Site 1015)

    Sioux Falls, South Dakota

  • Houston Methodist Hospital ( Site 1017)

    Houston, Texas

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)

    Kingston, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 1056)

    Toronto, Ontario, Canada

  • James Lind Centro de Investigacion del Cancer ( Site 1404)

    Temuco, Araucania, Chile

  • FALP-UIDO ( Site 1401)

    Santiago, Region M. de Santiago, Chile

  • Oncovida ( Site 1405)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 1402)

    Santiago, Region M. de Santiago, Chile

  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)

    Medellín, Antioquia, Colombia

  • Clinica de la Costa S.A.S. ( Site 1421)

    Barranquilla, Atlántico, Colombia

  • Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)

    Bogotá, Cundinamarca, Colombia

  • Oncologos del Occidente ( Site 1424)

    Pereira, Risaralda Department, Colombia

  • Fundación Cardiovascular de Colombia ( Site 1423)

    Piedecuesta, Santander Department, Colombia

  • Institut Curie ( Site 1152)

    Paris, France

  • CENTRE LEON BERARD-Medical oncology ( Site 1151)

    Lyon, Auvergne-Rhône-Alpes, France

  • Centre Georges François Leclerc ( Site 1155)

    Dijon, Cote-d Or, France

  • Institut Regional du Cancer Montpellier ( Site 1157)

    Montpellier, Herault, France

  • Gustave Roussy-medicine departement ( Site 1153)

    Villejuif, Paris, France

  • Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)

    Avignon, Vaucluse, France

  • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)

    Berlin, Germany

  • Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne

    Tübingen, Baden-Wurttemberg, Germany

  • Klinikum der Universität München Großhadern ( Site 1176)

    München, Bavaria, Germany

  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)

    Düsseldorf, North Rhine-Westphalia, Germany

  • Rambam Health Care Campus-Oncology ( Site 1141)

    Haifa, Israel

  • Hadassah Medical Center-Oncology ( Site 1142)

    Jerusalem, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 1144)

    Ramat Gan, Israel

  • Sourasky Medical Center-Oncology ( Site 1143)

    Tel Aviv, Israel

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.